Genmab at neutral by Merrill

Genmab was rated at neutral by Merrill Lynch analyst following the company's research and development data where the potential advantages of HuMax-CD20 over Rituxan in chronic therapy indications such as rheumatoid arthritis (RA) were explained. HuMax-CD20 benefits, compared to Rituxan, include superior efficacy, better long-term safety and possibly less frequent dosing, according to Genmab. Genmab is looking to complete a CD20 deal by mid-2007 at the latest, according to the analyst. Shares of the Copenhagen, Denmark, biotechnology company were down Dkr 2.50, or 0.92%, at Dkr 269.00. (Copenhagen: GEN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.